Merck & Co., Inc. (MRK)

NYSE · Rahway, New Jersey, USA · Founded 1891 · CEO Robert Davis

Valuation summary

$53.38 fair value versus $132.81 in the market, a difference of -59.8%. Rated Sell.

Fair value per share$53.38
Current share price$132.81
Upside / downside-59.8%
Bear case$28.42
Bull case$89.89
Discount rate (WACC)8.6%
Terminal growth2.20%
Market capitalisation$328B
EV / Sales5.5x

About Merck & Co., Inc.

Founded in 1891 as the US subsidiary of the German chemical firm Merck, becoming independent after the First World War. Headquartered in Rahway, New Jersey; Robert Davis is CEO. The company is defined by Keytruda, the PD-1 checkpoint inhibitor that is the best-selling drug in the world and treats a growing list of cancers. Other products include Gardasil for HPV, the Januvia diabetes franchise, and a large animal health division. Merck's central challenge is the Keytruda patent cliff arriving in 2028.

Investment case

  • Keytruda continues to add indications, and the subcutaneous Keytruda Qlex, which contributed $463M of second-quarter 2026 sales, can extend the franchise's effective life.
  • Animal health is a genuinely good, non-correlated business that the market largely ignores.
  • The valuation already discounts a sharp Keytruda cliff, which is why our model deliberately builds a decline year into the forecast.

Key risks

  • Keytruda is roughly half of revenue and loses exclusivity in 2028. This is one of the largest patent cliffs in industry history.
  • Gardasil demand in China collapsed and has not recovered.
  • The positive Phase 3 melanoma result for intismeran in August 2026 helps, but no pipeline asset has yet shown it can replace revenue on Keytruda's scale.

Recent developments

Revenue by segment

Oncology (Keytruda-led)50%
Vaccines17%
Animal Health12%
Other pharma21%

Five-year forecast

RevenueFree cash flow
Year 1$70.4B$8.8B
Year 2$73.8B$9.5B
Year 3$77.4B$10.2B
Year 4$81.2B$10.9B
Year 5$85.2B$11.7B

What the street says

The Keytruda cliff still dominates every conversation. Shares rose about 12% on the August 2026 intismeran melanoma data, which strengthened the bull argument that the pipeline and business development can fill the gap; bears say no pipeline can replace $30B of revenue.

Comparable companies: AZN · UNH · TMO · SYK · JNJ · NVS · MDT · BSX

Open the interactive model, price chart and sensitivity grid →